Total Payments
$28,781
2024 Payments
$13,109
Companies
27
Transactions
222
Medicare Patients
313
Medicare Billing
$28,731
Payment Breakdown by Category
Other$16,000 (55.6%)
Food & Beverage$6,368 (22.1%)
Travel$3,196 (11.1%)
Research$1,753 (6.1%)
Consulting$1,380 (4.8%)
Education$82.95 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,000 | 5 | 55.6% |
| Food and Beverage | $6,368 | 205 | 22.1% |
| Travel and Lodging | $3,196 | 3 | 11.1% |
| Unspecified | $1,753 | 7 | 6.1% |
| Consulting Fee | $1,380 | 1 | 4.8% |
| Education | $82.95 | 1 | 0.3% |
Payments by Type
General
$27,028
215 transactions
Research
$1,753
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. | $19,704 | 14 | $0 (2024) |
| ABBVIE INC. | $2,000 | 33 | $0 (2024) |
| LEO Pharma Inc. | $1,516 | 8 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $720.38 | 25 | $0 (2024) |
| Incyte Corporation | $612.76 | 29 | $0 (2024) |
| Eli Lilly and Company | $603.00 | 1 | $0 (2022) |
| Dermavant Sciences, Inc. | $562.98 | 12 | $0 (2024) |
| Amgen Inc. | $524.81 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $448.73 | 20 | $0 (2024) |
| Lilly USA, LLC | $321.88 | 18 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,109 | 114 | Verrica Pharmaceuticals Inc. ($7,683) |
| 2023 | $13,438 | 69 | Verrica Pharmaceuticals Inc. ($12,021) |
| 2022 | $1,063 | 23 | Eli Lilly and Company ($603.00) |
| 2021 | $43.72 | 3 | AbbVie Inc. ($15.81) |
| 2020 | $98.14 | 1 | AbbVie Inc. ($98.14) |
| 2019 | $604.44 | 7 | AbbVie, Inc. ($164.07) |
| 2018 | $425.05 | 5 | AbbVie, Inc. ($196.11) |
All Payment Transactions
222 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $20.34 | General |
| Category: Dermatology | ||||||
| 12/19/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $130.83 | General |
| Category: DERMATOLOGY | ||||||
| 12/11/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Dermatology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $18.55 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $21.47 | General |
| Category: Dermatology | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: Dermatology | ||||||
| 11/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Immunology | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Immunology | ||||||
| 11/14/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $25.34 | General |
| Category: DERMATOLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $10.69 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $8.75 | General |
| Category: IMMUNOLOGY | ||||||
| 11/10/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $765.58 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $49.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $34.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $24.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $24.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $249.66 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/07/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $42.58 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $20.46 | General |
| Category: Dermatology | ||||||
| 10/22/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: Immunology | ||||||
| 10/22/2024 | Lilly USA, LLC | TALTZ (Drug), EBGLYSS | Food and Beverage | In-kind items and services | $3.12 | General |
| Category: Immunology | ||||||
| 10/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $11.49 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | ABBVIE INC. | $1,150 | 6 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $603.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 172 | 290 | $31,420 | $15,110 |
| 2022 | 7 | 141 | 223 | $27,010 | $13,621 |
Total Patients
313
Total Services
513
Medicare Billing
$28,731
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 63 | 91 | $10,010 | $6,404 | 64.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 31 | $5,115 | $3,134 | 61.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 20 | 23 | $5,175 | $2,090 | 40.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 19 | 21 | $3,990 | $1,694 | 42.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 25 | 30 | $5,250 | $1,238 | 23.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 20 | 94 | $1,880 | $550.48 | 29.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 55 | $9,075 | $5,734 | 63.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 43 | $4,730 | $3,239 | 68.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 15 | 17 | $3,825 | $1,560 | 40.8% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 11 | 12 | $2,280 | $983.87 | 43.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 20 | 21 | $3,675 | $893.00 | 24.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,145 | $838.38 | 39.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 14 | 64 | $1,280 | $373.02 | 29.1% |
About Jennifer Ornelas
Jennifer Ornelas is a Dermatology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/21/2014. The National Provider Identifier (NPI) number assigned to this provider is 1013332451.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jennifer Ornelas has received a total of $28,781 in payments from pharmaceutical and medical device companies, with $13,109 received in 2024. These payments were reported across 222 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($16,000).
As a Medicare-enrolled provider, Ornelas has provided services to 313 Medicare beneficiaries, totaling 513 services with total Medicare billing of $28,731. Data is available for 2 years (2022–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Sacramento, CA
- Active Since 02/21/2014
- Last Updated 09/26/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1013332451
Products in Payments
- YCANTH (Drug) $19,704
- ADBRY (Biological) $1,516
- RINVOQ (Biological) $1,390
- DUPIXENT (Biological) $750.97
- OPZELURA (Drug) $612.76
- VTAMA (Drug) $562.98
- COSENTYX (Drug) $355.90
- TALTZ (Drug) $294.30
- Humira (Biological) $289.97
- TREMFYA (Drug) $267.52
- SKYRIZI (Biological) $250.03
- Enbrel (Biological) $216.73
- Otezla (Drug) $183.38
- SPEVIGO (Drug) $135.86
- Bimzelx (Biological) $125.84
- Winlevi (Drug) $125.82
- EPIDUO FORTE (Drug) $112.49
- LIBTAYO (Biological) $104.68
- Tremfya (Drug) $100.56
- COSENTYX (Biological) $92.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Sacramento
Dr. Raja Sivamani, M.d., M.s., A.h.e, M.D., M.S., A.H.E
Dermatology — Payments: $1.3M
Dermatology $1.3M
Dr. Emil Tanghetti, M.d, M.D
Dermatology — Payments: $1.0M
Dermatology $1.0M
Jacqueline Calkin, M.d, M.D
Dermatology — Payments: $130,291
Dermatology $130,291
Dr. Emanual Maverakis, M.d, M.D
Dermatology — Payments: $52,284
Dermatology $52,284
Alison Boudreaux, M.d, M.D
Dermatology — Payments: $46,728
Dermatology $46,728
Mirza Alikhan, Md, MD
Dermatology — Payments: $30,111
Dermatology $30,111